title: Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
abstract: Although the combination of gemcitabine and radiation produces a high frequency of complete responses in the treatment of locally advanced head and neck cancer, substantial toxicity suggests that an improvement in the therapeutic index is required. The purpose of this study was to determine if gefitinib could improve the efficacy of gemcitabine and if drug schedule is important. We hypothesized that gemcitabine followed by gefitinib would be superior to the opposite order because of both cell cycle and growth factor signaling interactions. Using UMSCC-1 cells in vitro, we confirmed that gefitinib arrested cells in G(1) and suppressed phospho-epidermal growth factor receptor (p(Y845)EGFR) and that gemcitabine arrested cells in S phase and stimulated p(Y845)EGFR. The schedule of gemcitabine followed by gefitinib caused arrest of cells in S phase. Gefitinib suppressed gemcitabine-mediated p(Y845)EGFR stimulation. This schedule caused decreased p(S473)AKT, increased poly(ADP-ribose) polymerase cleavage, and increased apoptosis compared with gemcitabine alone. The schedule of gefitinib followed by gemcitabine also caused suppression of p(Y845)EGFR but arrested cells in G(1). This schedule in which gefitinib was used first was associated with stable levels of p(S473)AKT and minimal poly(ADP-ribose) polymerase cleavage and apoptosis. These results were reflected in experiments in nude mice bearing UMSCC-1 xenografts, in which there was greater tumor regression and apoptosis when animals received gemcitabine followed by gefitinib during the first week of therapy. These findings suggest that the schedule of gemcitabine followed by gefitinib may increase the therapeutic index over gemcitabine alone and, combined with clinical data, encourage exploration of combination of gemcitabine, EGFR inhibitors, and radiation.
authors.affiliation: Department of Radiation Oncology, University of Michigan Medical School, 1331 East Ann Street, Ann Arbor, MI 48109, USA.
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Chun
authors.forename: Felix Y
authors.initials: FY
authors.lastname: Feng
authors.forename: Ashley M
authors.initials: AM
authors.lastname: Scheurer
authors.forename: Mary A
authors.initials: MA
authors.lastname: Davis
authors.forename: Theodore S
authors.initials: TS
authors.lastname: Lawrence
authors.forename: Mukesh K
authors.initials: MK
authors.lastname: Nyati
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004334:Drug Administration Schedule; D004347:Drug Interactions; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D000077156:Gefitinib; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D011799:Quinazolines / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D011799:Quinazolines; D003841:Deoxycytidine; D066246:ErbB Receptors; D000077156:Gefitinib; D000093542:Gemcitabine